-
-
Recent News
-
May 4, 2012
MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
-
May 1, 2012
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
-
April 12, 2012
-
-
-
Careers
Do you like to work in a fast paced, team-oriented environment with people committed to helping patients with neurological diseases? Explore our Careers section, meet our people and get to know us. We currently have opportunities for creative, experienced and talented individuals who want to join the MAP team.
Read More
-
-
LEVADEX®
LEVADEX® (dihydroergotamine, USP) inhalation aerosol is an orally inhaled investigational drug for the acute treatment of migraine in adults.

- © 2011 MAP Pharmaceuticals, Inc. All Rights Reserved.
- Privacy Policy
- Terms of Use
- Site Map